Securities Registration: Employee Benefit Plan (s-8)
February 16 2017 - 4:32PM
Edgar (US Regulatory)
Registration No. 333-
As filed with the Securities and Exchange Commission on February 16, 2017
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
MEI Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
Delaware
|
|
51-0407811
|
(State or other jurisdiction of
incorporation or organization)
|
|
(IRS Employer
Identification No.)
|
11975 El Camino Real, Suite 101
San Diego, CA 92130
(Address of Principal Executive Offices)(Zip Code)
MEI Pharma,
Inc. Amended and Restated 2008 Stock Omnibus Equity Compensation Plan
(Full title of the plan)
Daniel P. Gold
President & Chief Executive Officer
MEI Pharma, Inc.
11975
El Camino Real, Suite 101
San Diego, CA 92130
(858)
792-6300
(Name, address and telephone number of agent for service)
with copies to:
Steven A. Navarro, Esq.
Finnbarr D. Murphy, Esq.
Morgan, Lewis & Bockius LLP
101 Park Avenue
New
York, New York 10178
(212)
309-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule
12b-2
of the Exchange
Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☒
|
|
|
|
|
Non-accelerated filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Securities to be Registered
|
|
Amount to be
Registered
|
|
Proposed Maximum
Offering Price Per
Share
|
|
Proposed Maximum
Aggregate Offering
Price
|
|
Amount of
Registration Fee
|
Common Stock, par value $0.00000002 per share
|
|
3,500,000 shares(1)
|
|
$1.73(2)
|
|
$6,055,000(2)
|
|
$701.78(3)
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of the Registrants common stock issuable
pursuant to the MEI Pharma, Inc. Amended and Restated 2008 Stock Omnibus Equity Compensation Plan as a result of any stock dividend, stock split, recapitalization or other similar transaction.
|
(2)
|
Calculated pursuant to paragraphs (c) and (h) of Rule 457 of the Securities Act (based upon the average of the high and low sales price for the Registrants common stock as reported on the Nasdaq Capital
Market on February 14, 2017). The foregoing calculation is solely for the purpose of determining the registration fee.
|
(3)
|
Based upon the proposed maximum offering price per share, calculated as described in footnote (2) above.
|
EXPLANATORY NOTE
MEI Pharma, Inc. (formerly known as Marshall Edwards, Inc.) (we or the Company) previously filed a Registration
Statement on Form
S-8
(File
No. 333-156985)
(the Original Registration Statement) with respect to the Marshall Edwards, Inc. 2008 Stock Omnibus Equity
Compensation Plan (the Plan). On December 1, 2011, our stockholders approved an amendment and restatement of the Plan to increase the aggregate number of shares of our common stock, par value $0.00000002 per share (the Common
Stock) that may be subject to awards under the Plan by 1,800,000 shares. On February 21, 2012, we filed an additional Registration Statement on Form S-8 (File No. 333-179591) (the Second Registration Statement) to cover such
additional 1,800,000 shares of Common Stock. On December 3, 2014, our stockholders approved another amendment and restatement of the Plan to increase the aggregate number of shares of Common Stock that may be subject to awards under the Plan by an
additional 1,750,000 shares. On January 26, 2015, we filed an additional Registration Statement on Form S-8 (File No. 333-201703) (the Third Registration Statement) to cover such additional 1,750,000 shares of Common Stock. On December
3, 2015, our stockholders approved another amendment and restatement of the Plan to increase the aggregate number of shares of Common Stock that may be subject to awards under the Plan by an additional 2,750,000 shares. On August 24, 2016, we filed
an additional registration statement on Form S-8 (File No. 333-213278) (the Fourth Registration Statement and, together with the Original Registration Statement, the Second Registration Statement and the Third Registration Statement, the
Prior Registration Statements) to cover such additional 2,750,000 shares of Common Stock. On December 1, 2016, our stockholders approved another amendment and restatement of the Plan to increase the aggregate number of shares of Common
Stock that may be subject to awards under the Plan by an additional 3,500,000 shares. This Registration Statement covers such additional 3,500,000 shares of Common Stock. In accordance with General Instruction E of Form
S-8,
the contents of the Prior Registration Statements are incorporated herein by reference.
The
Amended and Restated 2008 Stock Omnibus Equity Compensation Plan filed herewith as Exhibit 4.1 replaces the Exhibit 4.2 previously filed with the Prior Registration Statements.
PART II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents previously filed by us with the Securities and Exchange Commission (the Commission) are incorporated by
reference into this Registration Statement:
|
(a)
|
Our Annual Report on Form
10-K
for the fiscal year ended June 30, 2016 filed with the Commission on September 6, 2016;
|
|
(b)
|
Our Quarterly Reports on Form
10-Q
for the fiscal quarter ended September 30, 2016, filed with the Commission on November 9, 2016, as amended on February 16, 2017, and
for the fiscal quarter ended December 31, 2016, filed with the Commission on February 8, 2017;
|
|
(c)
|
Our Current Reports on Form
8-K
filed with the Commission on August 9, 2016, August 17, 2016, September 6, 2016 and December 2, 2016;
|
|
(d)
|
Our Definitive Proxy Statement on Schedule 14A for the annual meeting of stockholders held on December 1, 2016, filed with the Commission on October 17, 2016; and
|
|
(e)
|
The description of the Registrants Common Stock contained in the Registrants Registration Statement on Form
S-1
(File No. 333-109129)
filed with the Commission on September 25, 2003 and any amendments or reports filed for the purpose of updating such description.
|
All documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the
Exchange Act), prior to the filing of a post-effective amendment which indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference
into this Registration Statement and to be a part hereof from the date of the filing of such documents.
Any statement contained herein or
in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in
any other
2
subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
See the attached Exhibit Index, which is incorporated herein by reference.
Item 9. Undertakings.
(a) The undersigned
Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective
Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
provided,
however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply to this Registration Statement on Form
S-8
if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
3
(2) That, for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act,
each filing of the Registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in
the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
4
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form
S-8
and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California,
on February 16, 2017.
|
|
|
MEI Pharma, Inc.
|
|
|
By:
|
|
/s/ Daniel P. Gold
|
Name:
|
|
Daniel P. Gold
|
Title:
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Daniel P. Gold and Thomas M. Zech, and each of them, as his true and
lawful
attorneys-in-fact
and agents, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to sign any
or all amendments or supplements to this Registration Statement, whether
pre-effective
or post-effective, and to file the same with all exhibits thereto and other documents in connection therewith, with the
SEC, granting unto said
attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or appropriate
to be done with respect to this Registration Statement or any amendments or supplements hereto in the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact
and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons, in the
capacities indicated, on February 16, 2017:
|
|
|
Signature
|
|
Title
|
|
|
/s/ Daniel P. Gold
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
Daniel P. Gold
|
|
|
|
/s/ Thomas M. Zech
|
|
Secretary, Chief Financial Officer
(Principal Financial and Accounting Officer)
|
Thomas M. Zech
|
|
|
|
/s/ Christine A. White
|
|
Chairman of the Board
|
Christine A. White
|
|
|
|
/s/ William D. Rueckert
|
|
Director
|
William D. Rueckert
|
|
|
|
/s/ Charles V. Baltic
|
|
Director
|
Charles V. Baltic
|
|
|
|
/s/ Thomas C. Reynolds
|
|
Director
|
Thomas C. Reynolds
|
|
|
|
/s/ Nicholas R. Glover
|
|
Director
|
Nicholas R. Glover
|
|
|
|
/s/ Kevan E. Clemens
|
|
Director
|
Kevan E. Clemens
|
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
4.1
|
|
Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (incorporated by reference to Exhibit 10.1 to the Companys Current Report on Form 8-K filed with the Commission on December 2, 2016 (File No.
000-50484)).
|
|
|
5.1
|
|
Opinion of Morgan, Lewis & Bockius LLP.
|
|
|
23.1
|
|
Consent of BDO USA, LLP.
|
|
|
23.3
|
|
Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1).
|
|
|
24.1
|
|
Power of Attorney (included on the signature page of this Registration Statement).
|
MEI Pharma (NASDAQ:MEIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
MEI Pharma (NASDAQ:MEIP)
Historical Stock Chart
From Apr 2023 to Apr 2024